-DOCSTART- -X- O
The -X- _ O
inflammatory -X- _ B-Patient
bowel -X- _ I-Patient
diseases -X- _ I-Patient
( -X- _ I-Patient
IBDs -X- _ I-Patient
) -X- _ I-Patient
, -X- _ I-Patient
including -X- _ I-Patient
Crohnâ€™s -X- _ I-Patient
disease -X- _ I-Patient
( -X- _ I-Patient
CD -X- _ I-Patient
) -X- _ I-Patient
and -X- _ I-Patient
ulcerative -X- _ I-Patient
colitis -X- _ I-Patient
( -X- _ I-Patient
UC -X- _ I-Patient
) -X- _ I-Patient
, -X- _ O
are -X- _ O
chronic -X- _ O
inflammatory -X- _ O
conditions -X- _ O
of -X- _ O
the -X- _ O
gastrointestinal -X- _ O
tract -X- _ O
and -X- _ O
involve -X- _ O
a -X- _ O
complicated -X- _ O
reciprocity -X- _ O
of -X- _ O
environmental -X- _ O
, -X- _ O
genetic -X- _ O
, -X- _ O
and -X- _ O
immunologic -X- _ O
factors. -X- _ O
Despite -X- _ O
substantial -X- _ O
advances -X- _ O
in -X- _ O
the -X- _ O
foundational -X- _ O
understanding -X- _ O
of -X- _ O
the -X- _ O
immunological -X- _ O
pathogenesis -X- _ O
of -X- _ O
IBD -X- _ O
, -X- _ O
the -X- _ O
detailed -X- _ O
mechanism -X- _ O
of -X- _ O
the -X- _ O
pathological -X- _ O
progression -X- _ O
in -X- _ O
IBD -X- _ B-Patient
remains -X- _ O
unknown. -X- _ O
In -X- _ O
addition -X- _ O
to -X- _ O
Th1 -X- _ O
/ -X- _ O
Th2 -X- _ O
cells -X- _ O
, -X- _ O
whose -X- _ O
role -X- _ O
in -X- _ O
IBD -X- _ O
has -X- _ O
been -X- _ O
previously -X- _ O
well -X- _ O
defined -X- _ O
, -X- _ O
recent -X- _ O
evidence -X- _ O
indicates -X- _ O
that -X- _ O
Th17 -X- _ O
cells -X- _ O
and -X- _ O
Tregs -X- _ O
also -X- _ O
play -X- _ O
a -X- _ O
crucial -X- _ O
role -X- _ O
in -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
IBD. -X- _ O
Diets -X- _ O
which -X- _ O
contain -X- _ O
excess -X- _ O
sugars -X- _ O
, -X- _ O
salt -X- _ O
, -X- _ O
and -X- _ O
fat -X- _ O
may -X- _ O
also -X- _ O
be -X- _ O
important -X- _ O
actors -X- _ O
in -X- _ O
the -X- _ O
pathogenesis -X- _ O
of -X- _ O
IBD -X- _ O
, -X- _ O
which -X- _ O
may -X- _ O
be -X- _ O
the -X- _ O
cause -X- _ O
of -X- _ O
high -X- _ O
IBD -X- _ O
incidence -X- _ O
in -X- _ O
western -X- _ O
developed -X- _ O
and -X- _ O
industrialized -X- _ O
countries. -X- _ O
Up -X- _ O
until -X- _ O
now -X- _ O
, -X- _ O
the -X- _ O
reason -X- _ O
for -X- _ O
the -X- _ O
variance -X- _ O
in -X- _ O
prevalence -X- _ O
of -X- _ O
IBD -X- _ O
between -X- _ O
developed -X- _ O
and -X- _ O
developing -X- _ O
countries -X- _ O
has -X- _ O
been -X- _ O
unknown. -X- _ O
This -X- _ O
is -X- _ O
partly -X- _ O
due -X- _ O
to -X- _ O
the -X- _ O
increasing -X- _ O
popularity -X- _ O
of -X- _ O
western -X- _ O
diets -X- _ O
in -X- _ O
developing -X- _ O
countries -X- _ O
, -X- _ O
which -X- _ O
makes -X- _ O
the -X- _ O
data -X- _ O
harder -X- _ O
to -X- _ O
interpret. -X- _ O
The -X- _ O
enterocrinins -X- _ B-Intervention
glucagon-like -X- _ I-Intervention
peptides -X- _ I-Intervention
( -X- _ I-Intervention
GLPs -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ I-Intervention
including -X- _ I-Intervention
GLP-1 -X- _ I-Intervention
and -X- _ I-Intervention
GLP-2 -X- _ I-Intervention
, -X- _ O
exhibit -X- _ B-Outcome
notable -X- _ I-Outcome
benefits -X- _ I-Outcome
on -X- _ I-Outcome
lipid -X- _ I-Outcome
metabolism -X- _ I-Outcome
, -X- _ I-Outcome
atherosclerosis -X- _ I-Outcome
formation -X- _ I-Outcome
, -X- _ I-Outcome
plasma -X- _ I-Outcome
glucose -X- _ I-Outcome
levels -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
maintenance -X- _ I-Outcome
of -X- _ I-Outcome
gastric -X- _ I-Outcome
mucosa -X- _ I-Outcome
integrity. -X- _ I-Outcome
In -X- _ O
addition -X- _ O
to -X- _ O
the -X- _ O
regulation -X- _ O
of -X- _ O
nutrient -X- _ O
metabolism -X- _ O
, -X- _ O
the -X- _ O
emerging -X- _ O
role -X- _ O
of -X- _ O
GLPs -X- _ B-Intervention
and -X- _ O
their -X- _ O
degrading -X- _ B-Intervention
enzyme -X- _ I-Intervention
dipeptidyl -X- _ I-Intervention
peptidase-4 -X- _ I-Intervention
( -X- _ I-Intervention
DPP-4 -X- _ I-Intervention
) -X- _ I-Intervention
in -X- _ O
gastrointestinal -X- _ O
diseases -X- _ O
has -X- _ O
gained -X- _ O
increasing -X- _ O
attention. -X- _ O
Therefore -X- _ O
, -X- _ O
here -X- _ O
we -X- _ O
review -X- _ O
the -X- _ O
function -X- _ O
of -X- _ O
the -X- _ O
DPP-4 -X- _ B-Intervention
/ -X- _ I-Intervention
GLP -X- _ I-Intervention
axis -X- _ O
in -X- _ O
IBD -X- _ B-Intervention
. -X- _ O

